USA – FDA awards two COA grants to study neurodevelopment disorders and nephrotic syndrome

The US Food and Drug Administration (FDA) announced the awarding of two grants under its Clinical Outcome Assessments (COAs) program to inform the selection of clinical trial endpoints for drugs to treat neurodevelopmental disorders (NDDs) and nephrotic syndrome.

The grants “provide avenues to advance the use of patient input as an important part of drug development that can foster innovation and the availability of safe and effective drugs,” said the agency’s 4 May announcement. They have been awarded to researchers at the University of Michigan, Northwestern University and Duke University…